|
Die Passagen Macrilen betreffend,sind durchaus interessant,wie ich finde. https://blueequity.io/r/31889 ... "Operator Our next question comes from the line of Esther Hong of Janney. Esther Hong So first, given the agreement with Novo included about three years of using Strongbridge's sales force and reimbursement team to promote Macrilen, can we still expect a commercial infrastructure to be in place for Recorlev if U.S. launch occurs after 2021? And then, second, how is the launch of Macrilen proceeding? How are endocrinologists viewing Macrilen? Thanks. Matthew Pauls So first of all, thanks for the question, Esther. Just with regard to timing, actually the way this is shaping up is, it's shaping up really nicely with regard to kind of continuity and fluidity with regard to our 23-person rare endocrine field-based commercial team. Filing in the third quarter of 2020 has us potentially launching in 2021. And the timing fits very, very nicely. So we actually kind of get the maximum benefit on a number of fronts from that perspective. I hope that makes sense. And then the second part of the question was related to Macrilen. It's not our asset anymore, so we're really not commenting on it. Our 23-person rare endocrine field force is out every day in partnership with Novo and they are working away. And that's really the only comment that we can make given the fact that we no longer own the asset. Esther Hong And are plans still that Novo will retain 16 members of the sales force for Macrilen? Matthew Pauls No. So the structure of the deal is for 2019, 2020 and 2021. Our 23 employees, so these are Strongbridge employees, are working with Novo on a daily basis on Macrilen in the rare endocrine space, but they are our employees. And at the end of that three year deal, they remain our employees. So there's no retainment component, there's no crossover of our employees over to Novo, et cetera. Does that make sense, Esther? Operator I'm showing no further questions at this time and I'd now like to turn the call over to Strongbridge Biopharma's CEO, Matthew Pauls for closing remarks. Mr. Pauls? Matthew Pauls Thank you. In summary, we are very encouraged by the discussions we've had with the FDA to-date and are focused on advancing the Recorlev clinical development program and regulatory submission as quickly as possible. The data we are generating from this Phase 3 program are providing important insights into the understanding of Cushing's syndrome and the use of Recorlev. We look forward to working with healthcare professionals and patients to raise awareness of Cushing's syndrome and to providing a potential new treatment option for this difficult devastating rare disease. Thank you for joining today's call and for your continued support. Operator Ladies and gentlemen, thank you for participating in today's conference. This does conclude the call. You may now disconnect. Everyone, have a wonderful day." Offensichtlich zahlt Novo die 23 Strongbridge Vertriebsmitarbeiter bis 2021 und die sind auf Tagesbasis an Macrilen dran... Ich denk mal eher,das war ein Goodie des macrilen deals an Strongbridge und Novo selber dürfte kaum annehmen,das die was nennenswertes auf die Reihe kriegen. Dazu ... "Annabel Samimy And then in that vein, though, do you have any sense as to what's going on with Macrilen, whether Novo Nordisk has prioritized or de-prioritized this program? I think that royalty is down quite a bit. Brian Davis No, I think, obviously the transaction closed in December as you may recall just really right before the beginning of the quarter and we looked at the first quarter as being one of transition. So the royalty, I'll say, it wasn't unexpected from our standpoint. It was somewhat nominal. More importantly, we have our 23-person field force that is being funded. Strategically that's of significant value to us as we hope to bring Recorlev along in the relative near term and have a field force already out there. But that $7 million to $8 million per year is a very significant revenue stream for us over the three year period...." Novo wird schon Gas geben,aber erst wen sie mit Aeterna durch sind,meine Meinung. |
|
| aus der Diskussion: | AEterna Zentaris AEZS 1000% Chance !? |
| Autor (Datum des Eintrages): | Skuld (01.05.19 23:20:03) |
| Beitrag: | 7,968 von 9,063 (ID:60467117) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |